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Since mesenchymal stromal/stem cells (MSCs) were discovered, researchers have been
drawn to study their peculiar biological features, including their immune privileged status
and their capacity to selectively migrate into inflammatory areas, including tumors. These
properties make MSCs promising cellular vehicles for the delivery of therapeutic molecules
in the clinical setting. In recent decades, the engineering of MSCs into biological vehicles
carrying anticancer compounds has been achieved in different ways, including the loading
of MSCs with chemotherapeutics or drug functionalized nanoparticles (NPs), genetic
modifications to force the production of anticancer proteins, and the use of oncolytic
viruses. Recently, it has been demonstrated that wild-type and engineered MSCs can
release extracellular vesicles (EVs) that contain therapeutic agents. Despite the
enthusiasm for MSCs as cyto-pharmaceutical agents, many challenges, including
controlling the fate of MSCs after administration, must still be considered. Preclinical
results demonstrated that MSCs accumulate in lung, liver, and spleen, which could
prevent their engraftment into tumor sites. For this reason, physical, physiological, and
biological methods have been implemented to increase MSC concentration in the target
tumors. Currently, there are more than 900 registered clinical trials using MSCs. Only a
small fraction of these are investigating MSC-based therapies for cancer, but the number
of these clinical trials is expected to increase as technology and our understanding of
MSCs improve. This review will summarize MSC-based antitumor therapies to generate
an increasing awareness of their potential and limits to accelerate their clinical translation.
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Mesenchymal stromal/stem cells (MSCs) play an important role
in restoring tissue homeostasis when injury or damage affects the
structural integrity of the tissue (Vizoso et al., 2019). MSCs can
be attracted to injury sites by following the gradient of chemo-
attractant molecules released by inflammatory cells. At the site of
damage, local factors such as hypoxia, cytokines, and Toll-like
receptor ligands induce the recruited MSCs to proliferate and
express growth factors that accelerate tissue regeneration (Rustad
and Gurtner, 2012). Tumors can also mobilize MSCs from
distant organs, including bone marrow and adipose tissue,
driving their engraftment into the tumor microenvironment by
inflammatory signals (Kidd et al., 2012; Chen and Song, 2019). It
has been shown that MSCs are strongly recruited by hepatic
carcinoma (Xie et al., 2017), breast cancer (Ma et al., 2015), and
glioma (Smith et al., 2015). These tumor environments consist of
many immune cells, which, alongside cancer cells, secrete soluble
factors that can directly regulate MSC chemotaxis and
recruitment to damaged tissues. For instance, interleukin (IL)-
6 facilitates MSC attraction into tumor sites (Rattigan et al.,
2010). An IL-8-dependent recruitment of MSCs was detected in
glioma (Ringe et al., 2007), and it has also been shown that
platelet-derived growth factor subunit B (PDGFB), vascular
endothelial growth factor (VEGF), and transforming growth
factor beta-1 (TGF-b1) can induce MSC migration (Schar
et al., 2015). Recently, it was revealed that C-X-C motif
chemokine receptor 4 (CXCR4) is one of the primary
chemokine receptors involved in the enrollment and tumor
tropism of MSCs (Kalimuthu et al., 2017). Other chemokines
and their receptors with a central role in MSC tumor homing are
C-C motif chemokine receptor 1 (CCR1), CCR7, CCR9, C-X3-C
motif chemokine ligand 1 (CX3CL1), CXCR5, and CXCR6
(Honczarenko et al., 2006; Feng and Chen, 2009; Bao et al.,
2012). In osteosarcoma, it has been shown that stromal cell-
derived factor 1 alpha (SDF-1a) is implicated in MSC
recruitment to neoplastic tissue. MSCs, in turn, stimulate the
migration of osteosarcoma cells by C-C motif chemokine ligand
5 (CCL5)/RANTES secretion (Xu et al., 2009), thereby favoring
the spread of cancer by providing metastatic osteosarcoma cells
with a favorable microenvironment (Tsukamoto et al., 2012).
Due to their well-documented tumor homing, MSCs become
part of the tumor stroma, generating fibrovascular cellular
elements, including endothelial cells or pericytes, and possibly
differentiating into tumor-associated fibroblasts, which are
involved in extracellular matrix remodeling (Kidd et al., 2012).
The natural and specific ability of MSCs to home and engraft into
malignant tissues, along with their immune privileged status,
availability, genotypic and phenotypic stability, expandability,
and proven safety record in clinical trials, make MSCs the ideal
cellular vehicle for the delivery of anticancer agents improving
their bioavailability versus more conventional approaches
(Housman et al., 2014; Christodoulou et al., 2018). Thus, the
engineering of MSCs to induce or enhance the production of
biomolecules can counteract cancer growth while (ideally)
sparing normal tissues. To achieve this, MSCs can be
functionalized to release molecules capable of inducing tumorFrontiers in Pharmacology | www.frontiersin.org 2cell death (Figure 1) (Grisendi et al., 2011). The strategies used to
convert MSCs into cellular vehicles for anticancer molecules can
be classified into two different types. The first category includes
nongenetic modifications of MSCs, such as loading with
nanoparticle carriers or drugs. The second consists of
approaches based on genetic modification of MSCs to induce
the expression of anticancer proteins or suicide genes.USING DRUG-LOADED MSCS TO
TARGET CANCER
Uptake and Release of Chemotherapeutic
Agents by MSCs
Because MSCs are relatively resistant to cytostatic and cytotoxic
chemotherapeutic agents, they can be loaded with drugs and
used for targeted anticancer therapy (Figure 1A). One method to
do so is to dissolve active compounds in the MSC culture media.
The MSCs can incorporate the anticancer drugs into the
cytoplasm and release it into the culture medium in a time-
dependent manner. Pessina et al. demonstrated that MSCs can
efficiently take up the chemotherapeutic agents doxorubicin
(DOXO), paclitaxel (PTX), and gemcitabine (GEM) and
release them in an active form, resulting in an inhibition of
tumor cell growth in vitro (Pessina et al., 1999; Pessina et al.,
2013; Pascucci et al., 2014; Cocce et al., 2017a; Cocce et al.,
2017b). In a leukemia xenograft mouse model, authors
demonstrated that PTX-primed MSCs exerted a strong
anticancer effect, inhibiting the proliferation of tumor cells and
vascularization of the neoplasia (Pessina et al., 2013). The
antitumor impact of primed MSCs is currently being
investigated in different types of cancer cells. Among others,
Bonomi et al. demonstrated in an in vitro 3D dynamic culture
system that PTX-MSCs suppress the growth of human myeloma
cells (Bonomi et al., 2017). Recently, the authors investigated the
mechanisms driving PTX release by loaded MSCs, discovering
that MSCs can also liberate PTX associated with extracellular
vesicles (EVs) acting as “natural anticancer liposomes”
(Perteghella et al., 2019). The use of EVs for drug delivery is
detailed later in this review.
MSCs and Nanoparticles
MSCs can also deliver drug-loaded nanoparticles (NPs) to
specific target sites (Figure 1A). Initial studies introduced
MSCs loaded with magnetic and fluorescently labeled NPs in
the field of diagnostic. Roger et al. showed that coumarin-6 dye-
loaded poly-lactic acid NPs (PLA-NPs) and lipid nanocapsules
(LNCs) were efficiently absorbed by MSCs in a concentration-
and time-dependent way without influencing the viability and
differentiation of MSCs (Roger et al., 2010). These findings
prompted the use of NPs loaded with anticancer compounds
in MSC-based drug delivery strategies. Originally, NPs were
developed to facilitate targeted drug delivery by increasing
drug stability; protecting nucleotides from degradation, thus
facilitating their entry into the nucleus; and prolonging the
effect of the delivered drug, allowing a dose reduction and aSeptember 2020 | Volume 11 | Article 529921
Golinelli et al. Arming MSC Versus Cancerpossible decrease in side effects. However, their immunogenicity
and uneven intratumoral distribution (due to the dense network
of collagen and the high interstitial fluid pressure in the tumor
environment) often limits their therapeutic potential and clinical
application (Li et al., 2016). Nonetheless, the use of MSCs as
cellular vehicles for drug-loaded NPs may be an effective option
to overcome the limitations in NP biodistribution. MSCs could
circumvent the activation of the immune system against NPs,
and because MSCs have the ability to migrate within tumor
tissue, they could enable entry of NPs into the tumor core
(Aggarwal and Pittenger, 2005). Cellular uptake of NPs can be
mediated by different mechanisms, including passive transport
and active endocytosis (Banerji and Hayes, 2007). NP
internalization by MSCs can be facilitated by receptor-
mediated uptake and is also affected by the cell proliferation
rate, time of exposure, and MSC culture conditions (Sadhukha
et al., 2014). To overcome inefficient drug loading by MSCs, NPs
can be linked to the cellular membrane of MSCs by covalent
conjugation or by physical association obtained by electrostatic
and hydrophobic interactions (Li et al., 2011). In addition, smart
NPs that control drug cargo release under tumor-specific or
external conditions, such as heat, low pH, the presence ofFrontiers in Pharmacology | www.frontiersin.org 3enzymes, and light, have also been designed (Lei et al., 2008;
Wang et al., 2011; Huang et al., 2013; Qian et al., 2015; Tian et al.,
2015). Sadhukha et al. demonstrated an effective tumor-targeting
strategy that consisted in engineering MSCs to carry poly(d,l-
lactide-co-glycolide) (PLGA) NPs loaded with PTX. In this
study, MSCs showed both concentration- and time-dependent
absorption of NPs, with scarce impact on key MSC features and a
dose-dependent cytotoxicity in lung and ovarian cancer cells
both in vitro and in vivo (Sadhukha et al., 2014). In other studies,
PLGA-PTX- or PLGA-DOX-loaded MSCs were found in
different cancer types, like prostate, lung and glioma (Pacioni
et al., 2015; Levy et al., 2016; Wang et al., 2016). In an orthotopic
lung tumor model, Layek et al. demonstrated that MSCs carrying
PTX-loaded NPs homed to cancer tissues and created cellular
drug storage that released the drug over the time. Although
containing significantly lower doses of PTX, treatment with
MSCs carrying PTX-NPs resulted in relevant reduction of
tumor growth, increased animal survival, and lower toxicity
compared to treatment with PTX solution or free PTX-NPs
(Layek et al., 2018).
Most of the nanoengineering strategies previously described
depend on simple endocytosis of drug-encapsulated NPs intoA B DC
FIGURE 1 | Mesenchymal stromal/stem cells (MSCs) can be functionalized using different strategies to release antitumor agents for cancer treatment.
(A) An anticancer drug is dissolved in the MSC culture media. MSCs incorporate the chemotherapeutic into the cytoplasm and then release it into the tumor
microenvironment. MSCs efficiently absorb doxorubicin (DOXO), paclitaxel (PTX), and gemcitabine (GEM) and release them in their active forms, inhibiting tumor cell
growth. MSCs can also take up drug-loaded nanoparticles (NPs), improving their biodistribution. (B) Using genetic modification, MSCs can be forced to express
suicide genes encoding specific enzymes (e.g., TK, CD) that convert nontoxic prodrugs (GCV, 5-FC) into active derivatives. The prodrugs are systemically
administered and then engineered MSCs are intravenously infused. Once injected, MSCs home into the tumor and convert the inactive prodrug into cytotoxic
metabolites inside the neoplastic tissue, thus minimizing the off-target toxicity. (C) Genetic modification of MSCs can be also performed to induce the production of
bioactive molecules and immunomodulatory cytokines such as interferons (e.g., IFN-a, IFN-b, IFN-g), interleukins (e.g., IL-2, IL-12, IL-15,IL-18), chemokines (e.g.,
CXC3L1), proapoptotic molecules (e.g., TRAIL), antiangiogenic molecules (e.g., Alpha-1 antitrypsin, NK4, VEGFR1), or molecules with other antitumor properties
(e.g., TNF-a, HNF4-a). These proteins can both act directly on tumor cells, inducing apoptosis, and potentiate the host inflammatory response through crosstalk with
tumor-infiltrating leukocytes. (D) MSCs act as carriers and amplifiers of oncolytic viruses, protecting the viruses from host immune responses and delivering them into
tumor sites.September 2020 | Volume 11 | Article 529921
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adequate drug loading and retention. To increase drug loading in
MSCs, Moku et al. developed PLGA NPs conjugated to the cell-
penetrating peptide transactivator of transcription (TAT). It was
found that TAT functionalization enhanced the intracellular
uptake and retainment of NPs in MSCs. Further, treatment
with MSCs carrying TAT-functionalized NPs loaded with PTX
resulted in a significant inhibition of tumor growth and higher
survival in a mouse orthotopic model of lung cancer compared to
free drug or NP-encapsulated drug (Moku et al., 2019). In
addition to these chemical NP delivery strategies, biological
NPs have recently emerged as new MSC-based delivery tools.GENETIC MODIFICATION OF MSCS TO
TARGET CANCER
Methods to genetically modify MSCs generally use viral vectors,
including retroviral, lentiviral, or adeno-associated viral vectors,
and DNA plasmids (Marofi et al., 2017). The choice of genetic
modification is driven by the aim and the target of the therapy.
Suicide Genes and MSCs
One approach to cancer treatment involves the delivery of suicide
genes by MSCs (Figure 1B). After gene manipulation with an
appropriate viral vector, MSCs can produce specific enzymes that
convert nontoxic prodrugs into active derivatives (Zhang et al.,
2015). The prodrugs are administered systemically following
intravenous infusion of engineered MSCs. The MSCs home to
tumors and convert these prodrugs into cytotoxic metabolites inside
the neoplastic tissue, thus minimizing the off-target toxicity. The
main advantage of this anticancer approach is the amplification of
the toxicity of the drug via the bystander effect, which leads to the
death of neighboring target cells due to indirect effects caused by
engineered MSCs. The cytotoxic effect exerted by the activated
prodrug additionally promotes the release of toxic substances that
activate immune cells, including cytotoxic T cells and macrophages,
leading to more effective cancer death (Zhang et al., 2015). The
production of drug metabolites is also highly toxic for the MSC
carriers themselves; thus, they die in the process, reducing a remote
risk of adverse effects (e.g., transformation events or protumorigenic
effects) related to the long-term persistence of homed and
nonhomed MSCs in patients at the end of treatment. Drugs with
a short half-life or high systemic toxicity, such as ganciclovir (GCV)
or 5-fluorouracil (5-FU), may be ideal candidates for gene-directed
enzyme prodrug therapy. For these agents, the systemic
concentrations required for a therapeutic effect are significantly
higher than the tolerated dose. Delivery of the agent directly into the
tumor would permit durable effects without the toxicities seen with
systemic delivery (Tsao et al., 2004). The most common enzyme-
prodrug complexes used in combination with MSCs to target
various tumors are herpes simplex virus thymidine kinase
complexed with GCV (HSV-TK/GCV system) and yeast cytosine
deaminase (CD) with 5-fluorocytosine (5-FC) (Kucerova et al.,
2007; Alieva et al., 2012). Adipose tissue-derived MSCs modified
to express yeast CD given in combination with 5-FC significantlyFrontiers in Pharmacology | www.frontiersin.org 4inhibit the growth of colon cancer in immunocompromised mice
(Kucerova et al., 2007). In this approach, MSCs home to the tumor
tissue and CD produced by the MSCs converts 5−FC to 5−FU, a
tumoricidal chemotherapeutic agent that can then diffuse into the
tumor tissue. Co-administration of CD−expressingMSCs and 5−FC
was also effective in treating melanoma and human prostate cancer
in mouse xenograft models (Kucerova et al., 2008; Cavarretta et al.,
2010). Similarly, it has been shown that TRAIL and HSV-TK-
modifiedMSCs in the presence of GCV significantly reduced tumor
growth and increased survival in mice bearing highly malignant
glioblastomamultiforme (GBM) (Martinez-Quintanilla et al., 2013).
MSCs Delivering Bioactive Molecules
Genetic modifications of MSCs can be also used to induce the
expression of anticancer bioactive molecules (Figure 1C). In
2002, MSCs were used for the first time for the targeted delivery
of interferon-beta (IFN-b) in an in vivo preclinical model of
human melanoma (Studeny et al., 2002). MSCs carrying IFN-b
were administered into tumor-bearing mice, provoking a
significant reduction in tumor growth and an increase in
survival compared to the control group. In addition, the
authors demonstrated that, after intravenous injection, the
engineered MSCs efficiently migrated and engrafted into lung
metastases, delivering IFN-b into the tumors. In addition to IFN-b,
other therapeutic genes encoding regulatory proteins and
immunomodulatory cytokines such as interferons (e.g., IFN-a,
IFN-b, IFN-g), interleukins (e.g., IL-2, IL-12, IL-15, IL-18), and
chemokines (e.g., CX3CL1), as well as molecules with
proapoptotic functions (e.g., tumor necrosis factor-related
apoptosis-inducing ligand [TRAIL]), antiangiogenic activities
(e.g., Alpha-1 antitrypsin, NK4, VEGF receptor 1 [VEGFR1]),
or other properties (e.g., tumor necrosis factor alpha [TNF-a],
hepatocyte nuclear factor 4-alpha [HNF-4a]) have been
implemented in preclinical studies (Shah, 2012). There are two
advantages of using genes coding for these molecules: first, these
proteins may act directly on tumor cells, blocking their
proliferation or inducing apoptosis; and second, because of
their physiological roles in the immune response, they can
potentiate the host inflammatory response via crosstalk with
leukocytes infiltrating the tumor microenvironment. IL-12
released by engineered MSCs not only exerts a direct
antitumor effect in mice with melanoma, lung cancer, and
hepatoma, but also activates cytotoxic lymphocytes and natural
killer (NK) cells, thereby significantly reducing metastasis (Chen
et al., 2008). Similar results were obtained in mouse models of
human glioma, renal carcinoma, and Ewing sarcoma (Duan
et al., 2009; Gao et al., 2010; Ryu et al., 2011). Umbilical cord
MSCs with enhanced IL-15 gene expression significantly
suppressed pancreatic tumor growth in mice and stimulated
accumulation of NK cells and CD8+ T lymphocytes in the tumor
microenvironment, thus supporting the antitumor immune
response (Jing et al., 2014). Co-expression of IL-18 and IFN-b
by bone marrow MSCs inhibited glioma growth in vivo and
prolonged the survival of glioma-bearing rats (Xu et al., 2015).
One of the most promising antitumor cytokines is TRAIL, which
selectively induces apoptosis in cancer cells, but not in most
normal cells. TRAIL is the ligand for death receptors that areSeptember 2020 | Volume 11 | Article 529921
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tumor cells, TRAIL can induce caspase-mediated apoptosis by
binding with its receptors death receptor 4 (DR4) and DR5
(Wong et al., 2019). MSCs display resistance to TRAIL due to
their low expression of both DR4 and DR5 (Grisendi et al., 2010).
In addition, is possible to consistently isolate and modify MSCs
from human adipose tissue by minimally invasive surgical
procedures (Foppiani et al., 2019; Starnoni et al., 2019). The
wild-type gene coding for membrane-bound TRAIL, as well as
modified cassettes expressing soluble ligand forms, have been
used in MSC-based therapeutic strategies, demonstrating
antitumor effects in vitro and in vivo in a wide variety of
human solid neoplasms, including lung cancer, pancreatic
cancer, glioblastoma, sarcoma, and hepatocarcinoma
(Loebinger et al., 2009; Sasportas LS et al., 2009; Grisendi et al.,
2010; Grisendi et al., 2011; Yan et al., 2014; D’Souza et al., 2015;
Grisendi et al., 2015; Guiho et al., 2016; Golinelli et al., 2018;
Candini et al., 2019; Rossignoli et al., 2019; Spano et al., 2019).
MSCs and Oncolytic Viruses
In addition to producing therapeutic molecules, MSCs have also
been used as carriers and amplifiers for the delivery of oncolytic
viruses into tumor sites (Figure 1D). An oncolytic virus is an
attenuated virus that can infect and kill cancer cells. After
infection, cancer cells are destroyed by oncolysis, releasing new
infectious virus particles that can stimulate a proinflammatory
environment to counteract immune evasion by malignant cells.
In this sense, oncolytic viruses not only cause direct destruction
of the tumor cells, but also stimulate host antitumor immune
responses to help destroy the remaining tumor. Most available
oncolytic viruses are engineered to increase tumor tropism and
to reduce virulence for nonneoplastic host cells. A number of
viruses, including adenovirus, reovirus, measles virus, herpes
simplex virus, Newcastle disease virus, and vaccinia virus, have
been clinically tested as oncolytic agents (Raja et al., 2018). When
oncolytic viruses are systemically administered, the host immune
cells recognize viruses as “non-self” and eliminates them before
they can reach the tumor site. Autologous MSCs, however, are
not recognized as foreign by the host immune system; thus, those
incorporating oncolytic viruses can reach the tumor without
major limitations (Nakashima et al., 2010). For this reason,
introduction of MSCs infected by an oncolytic adenovirus
demonstrated better antitumor effects and increased survival
compared to direct delivery of the oncolytic adenovirus in
xenograft models of ovarian cancer, glioma, and metastatic
lung cancer (Yong et al., 2009; Shah, 2012). This effect was due
to MSC-mediated defense of the oncolytic virus from host
immune system and transport of the viral particles to the
tumor location as it has been demonstrated in human glioma,
melanoma, breast cancer, lung metastasis, and liver cancer
models (Stoff-Khalili et al., 2007; Yong et al., 2009; Xia et al.,
2011; Ong et al., 2013). Interestingly, an engineered oncolytic
adenovirus carrying a TRAIL gene has been used to treat a mouse
model of pancreatic ductal adenocarcinoma (PDAC), a
malignant and deadly cancer characterized by an unfavorable
prognosis and limited therapeutic options. In this gene therapy
strategy, the oncolytic progeny released by engineered MSCsFrontiers in Pharmacology | www.frontiersin.org 5efficiently infects and lyses the tumor cells while simultaneously
provoking the apoptosis of noninfected tumor cells via the
expression of TRAIL molecules. The results collected in this
study indicated that in a PDAC mouse model, adipose tissue-
derived MSCs delivering TRAIL selectively homed to the tumor
site and strongly hampered tumor growth with no evident
toxicity or side effects (Kaczorowski et al., 2016).MSC-EXTRACELLULAR VESICLES FOR
ANTICANCER DRUG DELIVERY
How cancer cells recruit surrounding noncancer cells into the
tumor microenvironment remains a relevant and complex topic
(Kikuchi et al., 2019). In the last decade, investigators have begun
to focus on structures similar to dust particles that are released by
cells. These nanoparticles, known as extracellular vesicles (EVs),
are now studied worldwide and are recognized to be key carriers
of information in cell-to-cell communication. EVs are
membrane-bound nanostructures released by cells under
physiological and pathological conditions. They are classified
based on their size: exosomes (50–100 nm), microvesicles (100–
1,000 nm) and apoptotic bodies (over 1000 nm) (Colombo et al.,
2014; Lotvall et al., 2014). Present data suggest that tumor cell-
derived EVs are biologically important in cancer development,
suppressing tumor-directed immune responses and accelerating
tumor growth and invasiveness (Kikuchi et al., 2019).
The previously mentioned synthetic NPs used as drug
delivery systems to target cancer (Li et al., 2016) have raised
concerns due to their instability after administration, which may
be caused by immune reactions, the impact of uncontrolled in
vivo NP degradation on biocompatibility, and a lack of target
specificity (Feliu et al., 2016). In contrast, EVs may be a
promising therapeutic tool since they act as intercellular
messengers, carrying nucleic acids, lipids, proteins, and
miRNA, while maintaining their stability and integrity in
circulation, as demonstrated by their presence in most
biological fluids (Bruno et al., 2019). EVs are considered
nonimmunogenic and are able to protect their cargoes from
serum proteases and the immune system, avoiding phagocytosis
or degradation (Baek et al., 2019). The specific content of EVs
reflects the specific role of the producer cells and determines the
biological effect of the vesicles (Isola and Chen, 2017). The
current challenge among researchers is to convert this
biological message into a therapeutic one. Due to their
immunomodulatory capacity, their ability to home to tumor
sites, and their robust paracrine factors, MSCs may be a reliable
source of EVs for this purpose (Figure 2) (Witwer et al., 2019).
Growing evidence suggests that MSC-derived exosomes can
mediate the transfer of proteins and RNA to tumor cells.
However, whether these molecules suppress or promote tumor
growth is controversial (Parolini et al., 2009). Interestingly,
Roccaro et al. demonstrated that the content and the role of
exosomes differ depending on their source. Normal bone
marrow MSC (BM-MSC)-derived exosomes are associated with
tumor promotion, whereas those derived from multipleSeptember 2020 | Volume 11 | Article 529921
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(Roccaro et al., 2013). Several studies focused on the intrinsic
ability of MSC-derived EVs to counter tumor progression
(Figure 2A). S. Wu et al. demonstrated the capacity of EVs
produced by human Wharton’s Jelly-derived MSCs to abolish
tumor cell proliferation via G0/G1 phase arrest in a dose-
dependent manner (Wu et al., 2013). More recently, an in vitro
study demonstrated that BM-MSC-derived exosomes can inhibit
proliferation, migration, and invasion of pancreatic cancer cells
by transporting miR-126-3p, a known tumor suppressor (Wu
et al., 2019). Similarly, miRNA-100 seems to be involved in
tumor suppression mediated by MSC-derived exosomes.
Pakravan et al. demonstrated the ability of MSC-derived
exosomes to significantly decrease the expression and secretion
of VEGF in a dose-dependent manner in breast cancer-derived
cells (Pakravan et al., 2017). However, because MSCs are
heterogeneous, MSC-derived EVs may consequently exhibit
heterogeneity, which could be an important barrier to their
clinical use and should be taken into account (Del Fattore
et al., 2015). To circumvent the potential issues caused by theFrontiers in Pharmacology | www.frontiersin.org 6unpredictable effects of native MSC-derived EVs on tumor
growth, engineered EVs could be used instead. Current
strategies to obtain anticancer EVs are based on the ability of
MSCs to take up and release drugs, such as chemotherapeutic
agents (Figure 2B), or on genetic manipulations of donor cells
(Figure 2C) (Pessina et al., 2011). Interestingly, Pascucci et al.
demonstrated that BM-MSCs exposed to high concentrations of
PTX were able to survive and pack PTX into exosomes that could
efficiently deliver this active drug to human pancreatic
adenocarcinoma cells (Pascucci et al., 2014). The use of
exosomes to deliver miRNAs to treat malignant tumors with
poor prognosis, such as osteosarcoma or glioblastoma, has also
been investigated. In vitro studies demonstrated that the
introduction of synthetic miR-143 into MSCs increased the
secretion of exosome-encapsulated miR-143, which was able to
suppress the migration of the osteosarcoma cell line 143B
(Shimbo et al., 2014). Further in vitro studies investigated the
impact of exogenous miRNA mimics delivered by MSCs on
glioma cells and glioma stem cells (GSCs) (Bao et al., 2006).




FIGURE 2 | Mesenchymal stromal/stem cell (MSC)-Extracellular Vesicles (EVs) as anticancer drugs. (A) Native MSCs are a reliable source of EVs, which are able to
influence tumor cell proliferation, migration, and invasion. (B) Upon in vitro exposure to chemotherapeutic agents [e.g., paclitaxel (PTX)], MSCs internalize and pack
the drugs into therapeutic EVs that can efficiently deliver the active drugs to the neoplastic tissue, thus inducing tumor cell apoptosis or lysis. (C) MSCs can also be
genetically modified to express anticancer molecules (e.g., TRAIL) or miRNAs that can be secreted by MSC-derived EVs. (D) Alternatively, EVs are isolated from
MSCs and then loaded with drugs or biological cargo by simple diffusion or electroporation.September 2020 | Volume 11 | Article 529921
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migration and self-renewal, respectively (Lee et al., 2013). This
evidence demonstrates that exosomes can deliver miRNAs. This
ability, combined with their capacity to penetrate the blood–
brain barrier, makes exosomes a promising therapeutic tool
(Ha et al., 2016). Munoz et al. investigated the role of anti-
miR-9-loaded BM-MSC-derived exosomes in reversing the
chemoresistance of GBM cells (Munoz et al., 2013). Moreover,
in vivo studies in a rat brain tumor model demonstrated the
efficacy of intratumorally injected miR-146b-expressing MSC-
derived exosomes, once again supporting the use of exosomes
delivered by MSCs to treat malignant glioma (Katakowski et al.,
2013). Likewise, in vitro and in vivo studies showed that miR-
122-transfected adipose tissue-derived MSCs generate exosomes
containing miR-122, which is able to increase the sensitivity of
hepatocellular tumor cells to chemotherapeutic agents, thereby
providing a new therapeutic strategy (Lou et al., 2015). Similarly,
the decrease of miR-379 expression in breast cancer is connected
to its role as a tumor suppressor. Genetic manipulation of
parental MSCs resulted in the release of exosomes containing
miR-379 that, upon delivery to the tumor site, showed therapeutic
effects (O’Brien et al., 2018). As previously mentioned, TRAIL is a
promising anticancer agent (Wong et al., 2019), and TRAIL
secretion via EVs has been described as a natural approach to
deliver messages to near or distant sites that is used by several cell
types, including normal T cells upon activation (Monleon et al.,
2001) or human placental syncytiotrophoblasts (Stenqvist et al.,
2013). Yuan et al. reported an innovative potential anticancer
therapy based on EVs expressing surface TRAIL molecules
produced by TRAIL-transduced MSCs. These “armed” EVs
selectively induced apoptosis in cancer cells, supporting the use
of this alternative system for TRAIL delivery (Yuan et al., 2017).
The use of MSC-derived EVs in cancer therapy is promising
because they, like their producerMSCs, are able to home to cancer
sites (Wiklander et al., 2015). However, the exact functions of
MSC-derived EVs in tumor biology remain largely elusive, and
there are data suggesting that the acidic tumor microenvironment
is a key factor that drives the paracrine traffic of EVs within the
tumor mass (Parolini et al., 2009). To generate therapeutic EVs,
the most common method is to manipulate parental/producer
cells to generate EVs containing important cargo, such as
regulatory miRNAs or tumor suppressors. However, a passive
approach for drug or biological cargo incorporation into EVs is
also possible, as EVs can be loaded with drugs by diffusion, or by
electroporation when needed (Figure 2D) (Raimondo et al., 2019;
Vakhshiteh et al., 2019). Although EVs, particularly those derived
from MSCs, show promising properties, including high stability,
slow clearance, small size, lack of toxicity, and target specificity,
many challenges remain to be solved. In particular, exosome
isolation would need to be scaled up for clinical applications
(Vakhshiteh et al., 2019). This would require a robust
standardization of EV manipulation methods and, critically,
strict regulations for their clinical use in order to reduce
variability in their intracellular content and, consequently, in
their biological activities. Large-scale production requires
controlled conditions for EV isolation and purification, withFrontiers in Pharmacology | www.frontiersin.org 7attention to donor variability and differences between cell
sources. Moreover, the delivery route is critical for EV
biodistribution (Raimondo et al., 2019). Several studies support
the idea that MSC-derived EVs are able to accumulate in tumors
due to their capacity to identify the site of tumors or metastases
(Wiklander et al., 2015; Abello et al., 2019). Drug delivery can be
further improved by implementing new ex vivo modifications,
such as surface functionalization. Adding a synthetic
multifunctional peptide to EV surfaces substantially increases
the ability of the EVs to cross the blood–brain barrier and
accumulate in gliomas, enhancing the therapeutic effect of
loaded methotrexate (Ye et al., 2018). Despite the advantages of
using EVs instead of cells, several challenges remain. For example,
potency assays must be developed and appropriate dose findings
studies must be conducted (Phinney and Pittenger, 2017). Though
the enthusiasm for EVs may be warranted, we are currently far
from the safe and controlled clinical use of these biological shuttles.IMPROVING MSC TUMOR TARGETING
MSCs are currently evaluated in clinical trials to treat a variety of
diseases, with variable degrees of efficacy. For both locally and
systemically injected MSCs, there are issues with MSC fate post-
implantation, cell localization, and cell engraftment and survival in
the target tissue (Mastrolia et al., 2019). Once locally injected, cells
can be lost due to washout, cell death, and rejection by the
immune response (Kean et al., 2013). For systemic delivery, the
homing ability of MSCs has been showed for several tumors,
including gliomas (Nakamizo et al., 2005), breast (Yang et al.,
2019), colon (Knoop et al., 2015), ovarian (Komarova et al., 2010),
and lung carcinomas (Loebinger et al., 2009). However, only a
small amount of systemically administered MSCs effectively
reaches the target site (De Becker and Riet, 2016). Current
studies indicate that most MSCs accumulate in the lung, liver,
and spleen and are subsequently eliminated from the body, which
negatively impacts engraftment into the target site (Kean et al.,
2013). This suggests that a higher absolute number of cells is
needed to guarantee that a sufficient number of MSCs reaches the
damage site. However, producing a high number of MSCs is
technically challenging in the clinic, in particular for autologous
products generated within a cGMP environment. Hence, novel
targeting methods are needed to ameliorate MSC engraftment and
increase the therapeutic efficacy while reducing the number of cells
required and minimizing off-target effects (De Becker and Riet,
2016). MSCs are amenable to various targeting strategies,
including physical, physiological, and biological methods aimed
at increasing their concentration in the target site (Roth et al.,
2008). Physical targeting (Figure 3A) involves using either surgical
procedures or guiding strategies, such as catheters or external
magnets, to place cells directly into the site where the therapy is
needed (Arbab et al., 2004; Fiarresga et al., 2015; Silva et al., 2017).
Alternatively, therapeutic cells can be restrained in matrices or
devices that retain cells at the transplant site (Roth et al., 2008).
Notably, Shah et al. reported that MSC encapsulation in a
biodegradable, synthetic extracellular matrix significantly increasedSeptember 2020 | Volume 11 | Article 529921
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of antitumor proteins (Kauer et al., 2011; Shah, 2013; Duebgen et al.,
2014). An additional strategy relies on physiological processes
(Figure 3B), as the systemic circulation, to move the cells, instead
of using active cell-mediated migration (Roth et al., 2008). For
example, cells have a tendency to be trapped in the capillary of the
lungs. This is a first-pass mechanical barrier to systemic delivery.
However, this effect can be exploited to deliver MSC-mediated
therapies to the lungs (Hakkarainen et al., 2007; Stoff-Khalili et al.,
2007). Recently, biological targeting strategies (Figure 3C) have been
designed tomeet the need for higher target stringency upon systemic
infusion of MSCs, especially when the pathology to be treated is
widespread, as it is for metastases (Rosenblum et al., 2018). It
involves knowledge-driven approaches aimed at improving MSCs
homing, binding specificity to target tissue, and retention inside the
target environment (Roth et al., 2008). Different strategies have been
developed to manipulate MSC homing potential, including
modifying the MSC culture conditions to boost the expression ofFrontiers in Pharmacology | www.frontiersin.org 8homing-related molecules, engineering the cell membrane to
increase homing, and manipulating the target tissue to better
recruit MSCs (De Becker and Riet, 2016). For example, the
inherent homing potential of MSCs has been exploited by
exposing MSCs to glioma-conditioned media (Smith et al., 2015)
or to proinflammatory cytokines, such as TNF-a (Egea et al., 2011).
The ectopic expression of traffickingmachinery components, such as
CXCR1, significantly improved MSC tropism toward gliomas
secreting high levels of IL-8 (Kim et al., 2011). In addition,
radiation augments inflammatory signaling in the cancer site and
may be used to improve site-specific MSC migration (Klopp et al.,
2007). In parallel to efforts to improve MSC homing, researchers are
developing methods to improve MSC affinity for the target site.
Affinity-based targeting is dependent on binding interactions and
therefore exploits molecules that are exclusively or highly expressed
by the cells or tissue that we aim to target and that have affinity for
specific receptors on MSCs (Roth et al., 2008). Methods to improve
MSC affinity that do not involve genetic modification includeA
B
C
FIGURE 3 | Cell-based targeting strategies. Different targeting strategies to localize mesenchymal stromal/stem cell (MSC) carriers to the tissue of interest.
(A) Physical targeting relies on the use of devices, such as catheters or scaffolds, to position the cells where they are needed. (B) Physiological targeting takes
advantage of natural forces that route transplanted cells to specific sites or organs. Based on the infusion site, cells can be physiologically entrapped by the vascular
bed of specific tissues. (C) Biological targeting strategies embody a range of molecular techniques to target cell vehicles. Adapters such as bispecific antibodies, “cell
painting” with antibodies or peptides, and expression of artificial receptors enable the affinity-based retention of cell vehicles at the target site.September 2020 | Volume 11 | Article 529921
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antibodies, with applications currently restricted to regenerative
medicine (Gundlach et al., 2011; Kean et al., 2013). Most of the
work on tumor targeting strategies based on affinity has been done in
adoptive immunotherapy, the field in which the highest binding
capacity has been achieved, due to immune molecules such as T-cell
receptors (TCRs) and their derivatives and chimeric antigen
receptors (CARs) (Liu et al., 2019). Affinity-based cell targeting
has also recently been applied to MSCs to further optimize their
tumor-localizing potential (Golinelli et al., 2018). Balyasnikova et al.
genetically modified MSCs to express an artificial receptor (AR) that
recognizes EGFRvIII. This allowed the MSCs to specifically target
GBM cells expressing EGFRvIII, a mutated form of epidermal
growth factor receptor (EGFR) that is not present in healthy
tissues but has a high prevalence in GBM. The retention of
modified MSCs in EGFRvIII-expressing GBM was significantly
increased compared to unmodified MSCs (Balyasnikova et al.,
2010). Similarly, Komarova et al. showed that MSC surface
modification with an AR that binds to erbB2 increased MSC
engraftment and persistence in erbB2-positive ovarian tumors
(Komarova et al., 2010). However, evidence supporting targeted
anticancer molecule delivery by MSCs expressing an AR remains
sparse. The concept of targeted drug delivery as a “magic bullet” was
presented in 1908 by Paul Ehrlich and has inspired recent efforts
aimed at increasing the concentration of a drug in the tumor site by
modulating its affinity for a specific biological target (Strebhardt and
Ullrich, 2008). Taking inspiration from strategies used to redirect
lymphocyte specificity using CARs or bispecific adaptors, our group
coupled affinity and cytotoxicity by genetically modifying
therapeutic MSC-TRAIL to express an AR against the
disialoganglioside GD2 (Golinelli et al., 2018). The GD2-based
targeting allowed MSCs delivering TRAIL to be specifically
directed to GD2-expressing cancers, strengthening their adherence
to tumor cells. In developing this CAR-based anticancer strategy, we
aimed to reach site-specific and lasting retention of MSCs within the
tumor bed, thereby effectively delivering proapoptotic TRAIL
molecules to GD2-expressing tumors (Golinelli et al., 2018).
Combinatorial targeting has recently been applied by Segaliny and
colleagues, who produced MSCs that express P-selectin glycoprotein
ligand-1 (PSGL-1)/Sialyl-Lewis X (SLEX) together with modified
versions of CD and osteoprotegerin (OPG) to treat bone metastases
of breast cancer (Segaliny et al., 2019). MSC delivery to bones has
been improved through interactions between PSGL-1/SLEX and
selectins on activated endothelial cells, megakaryocytes, and platelets
in the tumor microenvironment. Once in the tumor niche,
engineered MSCs induced local cancer killing through a CD/5-FC
suicide gene therapy system and reduced osteolysis by expressing
modified OPG (Segaliny et al., 2019). Also noteworthy is the
technology developed by Zhu et al. aimed at simultaneously
targeting cell proliferation and death pathways in tumor cells using
MSCs armed with a bi-functional molecule comprised of a
nanobody targeting the EGFR (Enb) and TRAIL (Zhu et al.,
2017). EGFR is an excellent target, as it is commonly
overexpressed and/or altered in tumor, leading to abnormal cell
proliferation and activation of prosurvival pathways. The authors
demonstrated that the Enb-TRAIL bi-functional moleculeFrontiers in Pharmacology | www.frontiersin.org 9simultaneously engages both EGFR and DR5 on the surface of
tumor cells, leading to amplification of the apoptotic signal and
proving to be more effective than a combination treatment with Enb
and TRAIL. Using an orthotopic resection model of primary
glioblastoma, they showed that in vivo treatment with
encapsulated Enb-TRAIL MSCs reduced tumor growth and
considerably increased survival of tumor-bearing mice (Zhu et al.,
2017). Although each of the aforementioned tumor targeting
approaches individually improves MSC delivery, a combination of
different targeting approaches will be likely required to ameliorate
both the efficiency and the specificity of cell-based therapies in
cancer (Roth et al., 2008).MSCS AND CANCER TOWARD THE
CLINIC: ARE WE THERE YET?
Several trials have been designed to study MSCs and their possible
implications in cancer treatment. A proportion of these are based
on genetically modified MSCs. However, only four are using MSCs
as anticancer vehicles (Table 1). Among these trials, the Phase I/II
clinical trial TREAT-ME1, with the aim of evaluating the safety and
efficacy of MSCs delivering HSV-TK under the control of a CCL5
promoter (Einem et al., 2017). Preclinical studies had demonstrated
tumor growth reduction in models of hepatocellular and pancreatic
cancer, as well as a reduction in metastases (Niess et al., 2015).
Patients enrolled in the study were affected by advanced, recurrent,
or metastatic gastrointestinal or hepatopancreatobiliary
adenocarcinoma. The clinical trial protocol includes intravenous
injection of HSV-TK-engineered MSCs, followed by repeated GCV
injections. Intriguingly, this technology is based on CCL5, a
chemokine produced by MSCs upon contact with tumor cells,
which allows the activation of the CCL5 promoter driving HSV-TK
genes only in tumor-infiltrating MSCs, restricting expression of the
prodrug-converting enzyme to the tumor microenvironment. This
selective activation was introduced to reduce systemic adverse
effects. As primary endpoint, they demonstrated acceptable safety
and tolerability of the combined cell and gene therapy applied
(Einem et al., 2017). An ongoing Phase I clinical trial is studying the
best calibrated dose and the side effects of BM-MSCs loaded with
the oncolytic adenovirus DNX-2401 in patients affected by
recurrent GBM, gliosarcoma, or isocitrate dehydrogenase 1
(IDH1) wild-type anaplastic astrocytoma. DNX-2401 (Delta-24-





1. MSC-HSV-TK Gastrointestinal cancer (Niess et al., 2015; Einem
et al., 2017)
2. MSC-TRAIL Nonsmall cell lung cancer
(NSCLC)
(clinicaltrials.gov, 2017)
3. MSC-IFN-b Ovarian cancer (clinicaltrials.gov, 2015)
4. MSC- MV-NIS Ovarian cancer (clinicaltrials.gov, 2014)1
Golinelli et al. Arming MSC Versus Cancer(clinicaltrials.gov, 2019). The virus has been genetically modified to
make it safe for patients and capable of specifically targeting brain
cancer cells. This clinical trial has enrolled 36 patients who will be
monitored to determine the maximal tolerated dose and local/
systemic toxicity (clinicaltrials.gov, 2019). In 2017, a Phase I/II
clinical trial (TACTICAL) designed to evaluate the safety and
antitumor activity of allogenic MSC-TRAIL in combination with
chemotherapy in patients with metastatic nonsmall cell lung cancer
(NSCLC) was announced (clinicaltrials.gov, 2017). In Phase I,
patients received traditional chemotherapy on the first day,
followed by MSC-TRAIL cells on the second day. Each patient
received three cycles of treatment at 21-day intervals
(clinicaltrials.gov, 2017). Phase I was designed to assess safety and
to determine the recommended Phase II dose (RP2D) of MSC-
TRAIL when combined with chemotherapy. In Phase II of this trial,
which is double-blind, patients will be randomized to the
intervention group or the control one. All patients enrolled will
be treated by chemotherapy on the first day (clinicaltrials.gov, 2017).
However, patients randomized to the intervention group will receive
the RP2D of MSC-TRAIL on the second day, while the control
group will receive a placebo. The aim of Phase II will be to
determine tolerability and efficacy of treatment with MSC-TRAIL
in combination with traditional chemotherapy. In summary,
TACTICAL will be a key trial to verify the potential of MSC-
TRAIL to become a cell-based therapy for patients with advanced
lung cancer (clinicaltrials.gov, 2017). A similar therapeutic approach
using MSCs to treat PDAC has been announced. In this study, a
soluble trimeric and multimeric variant of TRAIL (sTRAIL) is
continuously released by adipose (AD)-MSCs and induces
apoptosis (Spano et al., 2019). The sTRAIL produced by AD-
MSCs that infiltrated the tumor stroma was able to significantly
inhibit tumor growth in vivo: substantial reductions in tumor mass
and in cytokeratin-7-positive cells, as well as an antiangiogenic
effect, were observed (Spano et al., 2019). The multiple roles of
MSCs in the tumor and their future applications in the clinic, were
recently reviewed by Lin and colleagues (Lin et al., 2019), who
emphasized the need to focus attention on the molecular
mechanism(s) of antitumorigenic activity. Additional studies
using MSC-based therapeutic approaches against cancer have
been reported. For example, nanodrug carriers can accumulate in
tumors due to the leaky tumor vasculature. In 2018, Layek et al.
investigated the use of MSCs carrying chemotherapy-loaded NPs as
cellular drug carriers. The goal was to generate cellular drug storage
capable of migrating to tumors and releasing the drug over a longFrontiers in Pharmacology | www.frontiersin.org 10period of time (Layek et al., 2018). The ability of MSCs to release
drugs is commonly employed in cancer therapies. Two registered
clinical trials are investigating MSCs for the treatment ovarian
cancer. The first one, is a Phase I clinical trial to test the safety
and to find the maximum tolerated dose of modified BM-MSCs
producing IFN-b that can be given to patients with ovarian cancer
(clinicaltrials.gov, 2015). The second, is a Phase I/II clinical trial
using AD-MSCs infected with an Edmonston’s strain measles virus
genetically engineered to produce sodium iodine symporter (MV-
NIS) to treat patients with recurrent ovarian cancer. In Phase I of
this trial, the maximum tolerated dose will be defined, and Phase II
will consist of intraperitoneal infusion of MV-NIS alone or MV-
NIS-modified MSCs. A successful five-year follow-up could lead to
an approval for the clinical use of MSCs carrying tumor-killing
substances directly to ovarian cancer cells (clinicaltrials.gov, 2014).
In conclusion, the use of MSCs for the treatment of cancer is a
promising option. The MSC-mediated delivery of genes,
proteins, oncolytic viruses or small molecules in the clinic will
take advantage of the abilities of MSCs to be modified and deliver
cargoes. While research have to address the MSC tumoral
migration/persistence to possibly overcome the limits of
nonspecific homing, the potential of combining cells with
chemotherapy agents will initiate and write new therapeutic
chapters in oncology.AUTHOR CONTRIBUTIONS
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